ARDMT

Analytical Review of DMT: Field Notes. New papers, trials, mechanisms, and sharp commentary on DMT research.

[ARDMT @ARDMTresearch]

The full piece is on ARDMT — the chemistry, the secrecy, the regional traditions, what serious research will need to specify going forward.
Long-form essays + daily field notes on DMT, ayahuasca, iboga, and the broader tryptamine research landscape.
https://t.co/XhqrXMdzeI

[ARDMT @ARDMTresearch]

In 2005 a chemist analysed 29 ayahuasca samples from four traditions.
Two contained no detectable DMT at all.
They were served as sacrament with the same reverence as the active brews.
I wrote a long piece this week on why "ayahuasca" denotes a family of substances, not one.

[ARDMT @ARDMTresearch]

The clinical implication: if "ayahuasca" denotes a chemically heterogeneous category, then trials administering different brews are not measuring the same intervention.
Much of the published clinical literature has been collapsing variation that is real, traceable, quantifiable.

[ARDMT @ARDMTresearch]

Six primer essays on the science of DMT and adjacent psychedelics, written for intelligent readers without a science background.
DMT, ayahuasca, 5-MeO-DMT, harmine, DMN, sigma-1.
Ahead of starting the MSc Psychedelics at Exeter, Sept 2026.
https://t.co/9y0KDmKelW

[ARDMT @ARDMTresearch]

Full review at ARDMT:
https://t.co/6YYYmiWHOL
The "unglamorous work that actually moves a field forward" line in the closing marginalia is doing real work — most psychedelic-neurodegeneration progress will look like this, not like single-shot Nature papers.

[ARDMT @ARDMTresearch]

DMT's therapeutic potential for neurodegeneration may run through the sigma-1 receptor — not the 5-HT2A receptor that makes it psychedelic.
If true, sub-psychedelic dosing becomes plausible. No perceptual fireworks required for the neuroprotection.
A🧵on the latest evidence!

[ARDMT @ARDMTresearch]

What would strengthen the case:
• Replication in an α-synuclein PFF model • Selective σ1R antagonist studies to confirm mechanism • PK data establishing CNS concentrations at sub-psychedelic doses
The Madrid group has been building this paper by paper. Slow accretion.

[ARDMT @ARDMTresearch]

ARDMT: Field Notes #9 — Exeter Saturday 9th May 2026
https://t.co/eQdGdW4SZ9

[ARDMT @ARDMTresearch]

@GoEnhanceAI Noice!

[Sinnerz @SinnerzsL]

Zantonsus - Astral Dreamer https://t.co/uJiK3NegcG